PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34471563-6	2021	Moreover, anwulignan increased the production of Nrf2, HO-1 and NQO1 proteins and decreased the production level of Keap1 protein in the renal tissue in the d-galactose induced aging mice.	macelignan	10-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	49-53
34471563-0	2021	Anwulignan alleviates d-galactose induced renal damage by regulating Nrf2/ARE signaling pathway in mice.	macelignan	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	69-73
34471563-5	2021	This study showed that anwulignan could significantly increase the kidney index, the creatinine clearance, the activities of superoxide dismutase, catalase and glutathione peroxidase; reduce the urinary protein concentration, the serum urea nitrogen and creatinine content, the content of malondialdehyde and 8-hydroxylated deoxyguanosine in the renal tissue; and improve the renal tissue damage.	macelignan	23-33	catalase	Mus musculus	147-155
34471563-6	2021	Moreover, anwulignan increased the production of Nrf2, HO-1 and NQO1 proteins and decreased the production level of Keap1 protein in the renal tissue in the d-galactose induced aging mice.	macelignan	10-20	heme oxygenase 1	Mus musculus	55-59
34471563-6	2021	Moreover, anwulignan increased the production of Nrf2, HO-1 and NQO1 proteins and decreased the production level of Keap1 protein in the renal tissue in the d-galactose induced aging mice.	macelignan	10-20	NAD(P)H dehydrogenase, quinone 1	Mus musculus	64-68
34471563-6	2021	Moreover, anwulignan increased the production of Nrf2, HO-1 and NQO1 proteins and decreased the production level of Keap1 protein in the renal tissue in the d-galactose induced aging mice.	macelignan	10-20	kelch-like ECH-associated protein 1	Mus musculus	116-121
34471563-7	2021	These results suggest that anwulignan significantly alleviates the renal damage by its antioxidant effect through regulating the production of Nrf2/ARE pathway-related proteins in the renal tissue in the d-galactose induced aging mice.	macelignan	27-37	nuclear factor, erythroid derived 2, like 2	Mus musculus	143-147
33437022-9	2021	Collectively, these results suggest that SWTX decreases I/R injury, and the PI3K/Akt/FoxO3a pathway takes part in protection during this process, gallogen (G3) and quercetin (G8) of GZ, methyleugenol (R2) and macelignan (R7) of RDK, santol (T1) of TX are responsible at least in part for SWTX"s cardioprotection effect.	macelignan	209-219	AKT serine/threonine kinase 1	Rattus norvegicus	81-84
33437022-9	2021	Collectively, these results suggest that SWTX decreases I/R injury, and the PI3K/Akt/FoxO3a pathway takes part in protection during this process, gallogen (G3) and quercetin (G8) of GZ, methyleugenol (R2) and macelignan (R7) of RDK, santol (T1) of TX are responsible at least in part for SWTX"s cardioprotection effect.	macelignan	209-219	forkhead box O3	Rattus norvegicus	85-91
32359384-12	2020	The activities of catalase and superoxide dismutase (SOD), and reduced glutathione (GSH) level were significantly reduced in IRI group, when compared with sham treated group, but were significantly and dose-dependently increased after treatment with macelignan (p < 0.05).	macelignan	250-260	catalase	Rattus norvegicus	18-26
32359384-16	2020	However, treatment with macelignan significantly and dose-dependently down-regulated the expressions of bax and caspase-3 in these cells, but significantly and dose-dependently upregulated the expression of bcl-2.	macelignan	24-34	BCL2 associated X, apoptosis regulator	Rattus norvegicus	104-107
32359384-16	2020	However, treatment with macelignan significantly and dose-dependently down-regulated the expressions of bax and caspase-3 in these cells, but significantly and dose-dependently upregulated the expression of bcl-2.	macelignan	24-34	caspase 3	Rattus norvegicus	112-121
32359384-16	2020	However, treatment with macelignan significantly and dose-dependently down-regulated the expressions of bax and caspase-3 in these cells, but significantly and dose-dependently upregulated the expression of bcl-2.	macelignan	24-34	BCL2, apoptosis regulator	Rattus norvegicus	207-212
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	interleukin 2	Mus musculus	64-68
32099340-12	2020	Conclusion: Anwulignan can restore the immune function that is declined in D-gal-induced aging mice partly related to its antioxidant capacity by activating the Nrf2/ARE pathway and downstream enzymes, as well as its anti-apoptotic effect by regulating Caspase-3 and the ratio of Bcl2 to Bax in the spleen.	macelignan	12-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	161-165
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	interleukin 4	Mus musculus	70-74
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	interferon gamma	Mus musculus	76-85
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	glutaminase 2 (liver, mitochondrial)	Mus musculus	101-104
32099340-12	2020	Conclusion: Anwulignan can restore the immune function that is declined in D-gal-induced aging mice partly related to its antioxidant capacity by activating the Nrf2/ARE pathway and downstream enzymes, as well as its anti-apoptotic effect by regulating Caspase-3 and the ratio of Bcl2 to Bax in the spleen.	macelignan	12-22	caspase 3	Mus musculus	253-262
32099340-12	2020	Conclusion: Anwulignan can restore the immune function that is declined in D-gal-induced aging mice partly related to its antioxidant capacity by activating the Nrf2/ARE pathway and downstream enzymes, as well as its anti-apoptotic effect by regulating Caspase-3 and the ratio of Bcl2 to Bax in the spleen.	macelignan	12-22	B cell leukemia/lymphoma 2	Mus musculus	280-284
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	tumor necrosis factor	Mus musculus	131-140
32099340-12	2020	Conclusion: Anwulignan can restore the immune function that is declined in D-gal-induced aging mice partly related to its antioxidant capacity by activating the Nrf2/ARE pathway and downstream enzymes, as well as its anti-apoptotic effect by regulating Caspase-3 and the ratio of Bcl2 to Bax in the spleen.	macelignan	12-22	BCL2-associated X protein	Mus musculus	288-291
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	interleukin 6	Mus musculus	145-149
30323572-10	2018	Furthermore, Anwulignan could upregulate the expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver, increase the HepG2 cell viability, and decrease caspase-3 contents in liver.	macelignan	13-23	mitogen-activated protein kinase 14	Homo sapiens	59-95
31696200-0	2019	Anti-fatigue effect of anwulignan via the NRF2 and PGC-1alpha signaling pathway in mice.	macelignan	23-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	42-46
31696200-0	2019	Anti-fatigue effect of anwulignan via the NRF2 and PGC-1alpha signaling pathway in mice.	macelignan	23-33	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	51-61
31696200-6	2019	RESULTS: Anwulignan significantly increased the exercise tolerance by decreasing BUN, LD, LDH, CK, Pi, MDA, TBARS, 8-OHdG, ROS, and Annexin V levels and increasing LG, MG, SOD, CAT, and GSH-Px levels, significantly upregulated the expression of NRF2 and Bcl2 proteins, which are anti-oxidation and anti-apoptosis regulators, and also activated the p38MAPK-PGC-1alpha pathway.	macelignan	9-19	annexin A5	Mus musculus	132-141
31696200-6	2019	RESULTS: Anwulignan significantly increased the exercise tolerance by decreasing BUN, LD, LDH, CK, Pi, MDA, TBARS, 8-OHdG, ROS, and Annexin V levels and increasing LG, MG, SOD, CAT, and GSH-Px levels, significantly upregulated the expression of NRF2 and Bcl2 proteins, which are anti-oxidation and anti-apoptosis regulators, and also activated the p38MAPK-PGC-1alpha pathway.	macelignan	9-19	catalase	Mus musculus	177-180
31696200-6	2019	RESULTS: Anwulignan significantly increased the exercise tolerance by decreasing BUN, LD, LDH, CK, Pi, MDA, TBARS, 8-OHdG, ROS, and Annexin V levels and increasing LG, MG, SOD, CAT, and GSH-Px levels, significantly upregulated the expression of NRF2 and Bcl2 proteins, which are anti-oxidation and anti-apoptosis regulators, and also activated the p38MAPK-PGC-1alpha pathway.	macelignan	9-19	nuclear factor, erythroid derived 2, like 2	Mus musculus	245-249
31696200-6	2019	RESULTS: Anwulignan significantly increased the exercise tolerance by decreasing BUN, LD, LDH, CK, Pi, MDA, TBARS, 8-OHdG, ROS, and Annexin V levels and increasing LG, MG, SOD, CAT, and GSH-Px levels, significantly upregulated the expression of NRF2 and Bcl2 proteins, which are anti-oxidation and anti-apoptosis regulators, and also activated the p38MAPK-PGC-1alpha pathway.	macelignan	9-19	B cell leukemia/lymphoma 2	Mus musculus	254-258
31696200-6	2019	RESULTS: Anwulignan significantly increased the exercise tolerance by decreasing BUN, LD, LDH, CK, Pi, MDA, TBARS, 8-OHdG, ROS, and Annexin V levels and increasing LG, MG, SOD, CAT, and GSH-Px levels, significantly upregulated the expression of NRF2 and Bcl2 proteins, which are anti-oxidation and anti-apoptosis regulators, and also activated the p38MAPK-PGC-1alpha pathway.	macelignan	9-19	mitogen-activated protein kinase 14	Mus musculus	348-355
31696200-6	2019	RESULTS: Anwulignan significantly increased the exercise tolerance by decreasing BUN, LD, LDH, CK, Pi, MDA, TBARS, 8-OHdG, ROS, and Annexin V levels and increasing LG, MG, SOD, CAT, and GSH-Px levels, significantly upregulated the expression of NRF2 and Bcl2 proteins, which are anti-oxidation and anti-apoptosis regulators, and also activated the p38MAPK-PGC-1alpha pathway.	macelignan	9-19	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	356-366
30323572-0	2018	Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK-Nrf2-HO-1 pathway in mice.	macelignan	21-31	mitogen-activated protein kinase 14	Mus musculus	94-102
30323572-0	2018	Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK-Nrf2-HO-1 pathway in mice.	macelignan	21-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	103-107
30486721-4	2019	This study aims to evaluate the inhibition of carboxylesterases (CESs) by the major ingredients isolated from Schisandra chinensis, including Anwuligan, Schisandrol B, Schisanhenol, deoxyschizandrin, and Schisandrin B.	macelignan	142-151	carboxylesterase 1	Homo sapiens	46-63
30323572-10	2018	Furthermore, Anwulignan could upregulate the expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver, increase the HepG2 cell viability, and decrease caspase-3 contents in liver.	macelignan	13-23	NFE2 like bZIP transcription factor 2	Homo sapiens	104-108
30323572-10	2018	Furthermore, Anwulignan could upregulate the expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver, increase the HepG2 cell viability, and decrease caspase-3 contents in liver.	macelignan	13-23	caspase 3	Homo sapiens	181-190
30323572-11	2018	Conclusion: Anwulignan has protective effects against the hepatic injury induced by d-gal, which may be related to its antioxidant capacity through activating p38 MAPK-Nrf2-HO-1 pathway, increases the injured cell viability, and decreases the caspase-3 contents in liver.	macelignan	12-22	mitogen-activated protein kinase 14	Mus musculus	159-167
30323572-11	2018	Conclusion: Anwulignan has protective effects against the hepatic injury induced by d-gal, which may be related to its antioxidant capacity through activating p38 MAPK-Nrf2-HO-1 pathway, increases the injured cell viability, and decreases the caspase-3 contents in liver.	macelignan	12-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	168-172
30323572-11	2018	Conclusion: Anwulignan has protective effects against the hepatic injury induced by d-gal, which may be related to its antioxidant capacity through activating p38 MAPK-Nrf2-HO-1 pathway, increases the injured cell viability, and decreases the caspase-3 contents in liver.	macelignan	12-22	caspase 3	Mus musculus	243-252
25099990-2	2014	This study aimed to characterize the metabolism of macelignan via the glucuronidation pathway and to identify the main UGT enzymes involved in macelignan glucuronidation.	macelignan	51-61	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	119-122
27383123-0	2016	Macelignan inhibits bee pathogenic fungi Ascophaera apis growth through HOG1 pathway.	macelignan	0-10	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	72-76
20600879-2	2010	The inhibition effect of macelignan on the CYP3A4-mediated metabolism was negligible over the concentration range of 0.01-100muM in rat liver microsome while approximately 33% inhibition was observed at 100muM in human liver microsome, implying that the interaction of macelignan with CYP3A4 might be insignificant at the physiologically achievable concentrations.	macelignan	25-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
22729280-2	2012	To evaluate the anti-allergic effects of macelignan isolated from Myristica fragrans Houtt., we determined its ability to inhibit calcium (Ca(2+)) influx, degranulation, and inflammatory mediator production in RBL-2 H3 cells stimulated with A23187 and phorbol 12-myristate 13-acetate.	macelignan	41-51	RB transcriptional corepressor like 2	Rattus norvegicus	210-215
20600879-6	2010	In conclusion, macelignan appeared to be effective to improve the cellular accumulation as well as oral exposure of paclitaxel mainly via the inhibition of P-gp-mediated cellular efflux, suggesting that the concomitant use of macelignan may provide a therapeutic benefit in improving the anticancer efficacy of paclitaxel.	macelignan	226-236	phosphoglycolate phosphatase	Homo sapiens	156-160
23643632-7	2013	With the administration of macelignan, interleukin-4 (IL-4) producing cells, but not interferon-gamma (IFN-gamma) or IL-17 producing cells, were diminished in the lungs.	macelignan	27-37	interleukin 4	Mus musculus	39-52
23643632-7	2013	With the administration of macelignan, interleukin-4 (IL-4) producing cells, but not interferon-gamma (IFN-gamma) or IL-17 producing cells, were diminished in the lungs.	macelignan	27-37	interleukin 4	Mus musculus	54-58
21532167-0	2011	Macelignan inhibits melanosome transfer mediated by protease-activated receptor-2 in keratinocytes.	macelignan	0-10	F2R like trypsin receptor 1	Homo sapiens	52-81
21532167-11	2011	Macelignan inhibits melanosome transfer by downregulating PAR-2, thereby reducing keratinocyte phagocytosis and PGE2 secretion, which in turn inhibits dendrite formation in B16F10 melanoma cells.	macelignan	0-10	pulmonary adenoma resistance 2	Mus musculus	58-63
20600879-2	2010	The inhibition effect of macelignan on the CYP3A4-mediated metabolism was negligible over the concentration range of 0.01-100muM in rat liver microsome while approximately 33% inhibition was observed at 100muM in human liver microsome, implying that the interaction of macelignan with CYP3A4 might be insignificant at the physiologically achievable concentrations.	macelignan	25-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	285-291
20600879-3	2010	In contrast, macelignan (20muM) increased the cellular accumulation of paclitaxel by approximately 1.7-fold in NCI/ADR-RES cells overexpressing P-gp, while it did not alter the cellular accumulation of paclitaxel in OVCAR-8 cells lacking P-gp.	macelignan	13-23	phosphoglycolate phosphatase	Homo sapiens	144-148
20600879-6	2010	In conclusion, macelignan appeared to be effective to improve the cellular accumulation as well as oral exposure of paclitaxel mainly via the inhibition of P-gp-mediated cellular efflux, suggesting that the concomitant use of macelignan may provide a therapeutic benefit in improving the anticancer efficacy of paclitaxel.	macelignan	15-25	phosphoglycolate phosphatase	Homo sapiens	156-160
19838926-1	2009	The effect of macelignan, a phytoestrogen, on P-gp function was investigated using multidrug resistant cancer cells overexpressing P-gp (NCI/ADR-RES) and the fluorescent P-gp substrates, daunorubicin and rhodamine 123.	macelignan	14-24	phosphoglycolate phosphatase	Homo sapiens	46-50
19914807-6	2010	We then explored the inhibitory effects of macelignan on UVB-induced MMP-9 and COX-2 and investigated the molecular mechanism underlying those effects.	macelignan	43-53	matrix metallopeptidase 9	Homo sapiens	69-74
19914807-6	2010	We then explored the inhibitory effects of macelignan on UVB-induced MMP-9 and COX-2 and investigated the molecular mechanism underlying those effects.	macelignan	43-53	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-84
19914807-11	2010	An inhibitory effect was also seen in the signal transduction network, where macelignan treatment reduced the activation of UVB-induced MAPKs, PI3K/Akt, and their downstream transcription factors.	macelignan	77-87	AKT serine/threonine kinase 1	Homo sapiens	148-151
19914807-12	2010	CONCLUSION: These results suggest that macelignan protects skin keratinocytes from UVB-induced damage and inhibits MMP-9 and COX-2 expression by attenuating the activation of MAPKs and PI3K/Akt.	macelignan	39-49	matrix metallopeptidase 9	Homo sapiens	115-120
19914807-12	2010	CONCLUSION: These results suggest that macelignan protects skin keratinocytes from UVB-induced damage and inhibits MMP-9 and COX-2 expression by attenuating the activation of MAPKs and PI3K/Akt.	macelignan	39-49	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	125-130
19914807-12	2010	CONCLUSION: These results suggest that macelignan protects skin keratinocytes from UVB-induced damage and inhibits MMP-9 and COX-2 expression by attenuating the activation of MAPKs and PI3K/Akt.	macelignan	39-49	AKT serine/threonine kinase 1	Homo sapiens	190-193
19483320-5	2009	The results show that macelignan suppresses both the phosphorylations of MAPKs and the degradation of inhibitory-kappa B (IkappaBalpha) and increases of nuclear NF-kappaB in LPS-stimulated BV-2 microglial cells.	macelignan	22-32	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	122-134
19483320-5	2009	The results show that macelignan suppresses both the phosphorylations of MAPKs and the degradation of inhibitory-kappa B (IkappaBalpha) and increases of nuclear NF-kappaB in LPS-stimulated BV-2 microglial cells.	macelignan	22-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	161-170
19838926-1	2009	The effect of macelignan, a phytoestrogen, on P-gp function was investigated using multidrug resistant cancer cells overexpressing P-gp (NCI/ADR-RES) and the fluorescent P-gp substrates, daunorubicin and rhodamine 123.	macelignan	14-24	phosphoglycolate phosphatase	Homo sapiens	131-135
19838926-1	2009	The effect of macelignan, a phytoestrogen, on P-gp function was investigated using multidrug resistant cancer cells overexpressing P-gp (NCI/ADR-RES) and the fluorescent P-gp substrates, daunorubicin and rhodamine 123.	macelignan	14-24	phosphoglycolate phosphatase	Homo sapiens	131-135
19838926-4	2009	Furthermore, cancer cells were more susceptible to the cytotoxicity of vinblastine, a P-gp substrate, in the presence of macelignan.	macelignan	121-131	phosphoglycolate phosphatase	Homo sapiens	86-90
19838926-5	2009	Those results suggest that macelignan has inhibitory effects on P-gp mediated cellular efflux.	macelignan	27-37	phosphoglycolate phosphatase	Homo sapiens	64-68
19838926-7	2009	Taken all together, macelignan was identified as a novel inhibitor of P-gp activity and may be a promising lead compound for the rational design of more efficacious drugs to reverse multidrug resistance in cancer.	macelignan	20-30	phosphoglycolate phosphatase	Homo sapiens	70-74
18065517-2	2008	This study evaluated the function of macelignan, a natural compound isolated from Myristica fragrans, as a dual agonist for PPARalpha/gamma and investigated its antidiabetes effects in animal models.	macelignan	37-47	peroxisome proliferator activated receptor alpha	Mus musculus	124-133
18065517-10	2008	CONCLUSIONS: Macelignan enhanced insulin sensitivity and improved lipid metabolic disorders by activating PPARalpha/gamma and attenuating ER stress, suggesting that it has potential as an antidiabetes agent for the treatment of type 2 diabetes.	macelignan	13-23	peroxisome proliferator activated receptor alpha	Mus musculus	106-115
18239286-0	2008	Protective Effects of macelignan on cisplatin-induced hepatotoxicity is associated with JNK activation.	macelignan	22-32	mitogen-activated protein kinase 8	Mus musculus	88-91
18239286-5	2008	The results also showed that the protective effects of macelignan on cisplatin-induced hepatotoxicity may be associated with the mitogen activated protein kinase (MAPK) signaling pathway.	macelignan	55-65	mitogen-activated protein kinase 1	Mus musculus	163-167
18239286-6	2008	Cisplatin-induced phosphorylation of c-Jun N-terminal kinase1/2 (JNK1/2) and extracellular signal-regulated kinase1/2 (ERK1/2) was abrogated by pretreatment with macelignan, however, that of p38 was not significantly affected.	macelignan	162-172	mitogen-activated protein kinase 8	Mus musculus	37-63
18239286-6	2008	Cisplatin-induced phosphorylation of c-Jun N-terminal kinase1/2 (JNK1/2) and extracellular signal-regulated kinase1/2 (ERK1/2) was abrogated by pretreatment with macelignan, however, that of p38 was not significantly affected.	macelignan	162-172	mitogen-activated protein kinase 8	Mus musculus	65-71
18239286-6	2008	Cisplatin-induced phosphorylation of c-Jun N-terminal kinase1/2 (JNK1/2) and extracellular signal-regulated kinase1/2 (ERK1/2) was abrogated by pretreatment with macelignan, however, that of p38 was not significantly affected.	macelignan	162-172	mitogen-activated protein kinase 3	Mus musculus	77-117
18239286-6	2008	Cisplatin-induced phosphorylation of c-Jun N-terminal kinase1/2 (JNK1/2) and extracellular signal-regulated kinase1/2 (ERK1/2) was abrogated by pretreatment with macelignan, however, that of p38 was not significantly affected.	macelignan	162-172	mitogen-activated protein kinase 3	Mus musculus	119-125
18239286-6	2008	Cisplatin-induced phosphorylation of c-Jun N-terminal kinase1/2 (JNK1/2) and extracellular signal-regulated kinase1/2 (ERK1/2) was abrogated by pretreatment with macelignan, however, that of p38 was not significantly affected.	macelignan	162-172	mitogen-activated protein kinase 14	Mus musculus	191-194
18239286-8	2008	Accordingly, it is suggested that the hepatoprotective effects of macelignan could be related to activation of the MAPK signaling pathway, especially JNK and c-Jun, its substrate.	macelignan	66-76	mitogen-activated protein kinase 1	Mus musculus	115-119
18239286-8	2008	Accordingly, it is suggested that the hepatoprotective effects of macelignan could be related to activation of the MAPK signaling pathway, especially JNK and c-Jun, its substrate.	macelignan	66-76	mitogen-activated protein kinase 8	Mus musculus	150-153
18239286-8	2008	Accordingly, it is suggested that the hepatoprotective effects of macelignan could be related to activation of the MAPK signaling pathway, especially JNK and c-Jun, its substrate.	macelignan	66-76	jun proto-oncogene	Mus musculus	158-163
15305043-3	2004	The intracellular caspase-3 activity of macelignan (4), oleiferin C (7), meso-dihydroguaiaretic acid (8), and licarin A (9) increased approximately 3.04, 6.16, 2.10, and 3.10-fold at 100 microM over that of untreated control.	macelignan	40-50	caspase 3	Homo sapiens	18-27
17611289-0	2007	Macelignan protects HepG2 cells against tert-butylhydroperoxide-induced oxidative damage.	macelignan	0-10	telomerase reverse transcriptase	Homo sapiens	40-44